JP2021120379A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021120379A5 JP2021120379A5 JP2021072166A JP2021072166A JP2021120379A5 JP 2021120379 A5 JP2021120379 A5 JP 2021120379A5 JP 2021072166 A JP2021072166 A JP 2021072166A JP 2021072166 A JP2021072166 A JP 2021072166A JP 2021120379 A5 JP2021120379 A5 JP 2021120379A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- formula
- compound
- insomnia
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 18
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 15
- 206010022437 insomnia Diseases 0.000 claims 10
- 208000007848 Alcoholism Diseases 0.000 claims 6
- 208000025746 alcohol use disease Diseases 0.000 claims 6
- 239000002552 dosage form Substances 0.000 claims 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 230000005976 liver dysfunction Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000020685 sleep-wake disease Diseases 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 1
- 229960004047 acamprosate Drugs 0.000 claims 1
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 claims 1
- 239000007894 caplet Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960002563 disulfiram Drugs 0.000 claims 1
- 229960002464 fluoxetine Drugs 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- 239000007897 gelcap Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- -1 nalmephenem Chemical compound 0.000 claims 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims 1
- 229960004127 naloxone Drugs 0.000 claims 1
- 229960003086 naltrexone Drugs 0.000 claims 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000006191 orally-disintegrating tablet Substances 0.000 claims 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims 1
- 229960004431 quetiapine Drugs 0.000 claims 1
- 229960004394 topiramate Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662366960P | 2016-07-26 | 2016-07-26 | |
| US62/366,960 | 2016-07-26 | ||
| US201762536097P | 2017-07-24 | 2017-07-24 | |
| US62/536,097 | 2017-07-24 | ||
| JP2019503994A JP7198197B2 (ja) | 2016-07-26 | 2017-07-25 | 睡眠障害の治療及び予防 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503994A Division JP7198197B2 (ja) | 2016-07-26 | 2017-07-25 | 睡眠障害の治療及び予防 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021120379A JP2021120379A (ja) | 2021-08-19 |
| JP2021120379A5 true JP2021120379A5 (https=) | 2021-12-02 |
| JP7291172B2 JP7291172B2 (ja) | 2023-06-14 |
Family
ID=59714072
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503994A Active JP7198197B2 (ja) | 2016-07-26 | 2017-07-25 | 睡眠障害の治療及び予防 |
| JP2021072166A Active JP7291172B2 (ja) | 2016-07-26 | 2021-04-21 | 睡眠障害の治療及び予防 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503994A Active JP7198197B2 (ja) | 2016-07-26 | 2017-07-25 | 睡眠障害の治療及び予防 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10974081B2 (https=) |
| EP (1) | EP3490563A1 (https=) |
| JP (2) | JP7198197B2 (https=) |
| KR (2) | KR102210209B1 (https=) |
| CN (1) | CN109689058B (https=) |
| AU (2) | AU2017304898B2 (https=) |
| BR (1) | BR112019001457A2 (https=) |
| CA (1) | CA3031388C (https=) |
| CL (1) | CL2019000190A1 (https=) |
| EC (1) | ECSP19014247A (https=) |
| IL (1) | IL264294B (https=) |
| JO (1) | JOP20190008A1 (https=) |
| MX (1) | MX388469B (https=) |
| NZ (1) | NZ750817A (https=) |
| PH (1) | PH12019500177A1 (https=) |
| SG (1) | SG11201900486WA (https=) |
| TN (1) | TN2019000019A1 (https=) |
| TW (1) | TWI661827B (https=) |
| WO (1) | WO2018020418A1 (https=) |
| ZA (1) | ZA201901055B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190008A1 (ar) | 2016-07-26 | 2019-01-24 | Purdue Pharma Lp | علاج ومنع اضطرابات النوم |
| JP7108041B2 (ja) * | 2018-01-24 | 2022-07-27 | パーデュー、ファーマ、リミテッド、パートナーシップ | 睡眠障害の治療及び予防 |
| CA3097445A1 (en) * | 2018-04-16 | 2019-10-24 | Technologies Hop-Child, Inc. | Systems and methods for the determination of arousal states, calibrated communication signals and monitoring arousal states |
| KR102198846B1 (ko) * | 2018-06-29 | 2021-01-05 | 다인기술 주식회사 | 배뇨에 관한 설문을 수행하는 방법, 시스템 및 비일시성의 컴퓨터 판독 가능 기록 매체 |
| US11547350B2 (en) | 2018-12-26 | 2023-01-10 | Industrial Technology Research Institute | Personalized parameter learning method, sleep-aid device and non-transitory computer readable medium |
| CN111359074B (zh) * | 2018-12-26 | 2022-08-02 | 财团法人工业技术研究院 | 个人化参数学习方法、睡眠辅助装置及存储介质 |
| CN113301957A (zh) * | 2019-01-31 | 2021-08-24 | 普渡制药公司 | 取代的喹喔啉型桥接哌啶化合物的多晶型形式 |
| BR112022004576A2 (pt) * | 2019-09-13 | 2022-06-14 | Takeda Pharmaceuticals Co | Métodos para diminuir ou tratar sonolência excessiva, tratar narcolepsia tipo 2 ou hipersonia idiopática, tratar distúrbio de trabalho de turno, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, diminuir ou melhorar sonolência subjetiva, aumentar insônia ou diminuir sonolência excessiva, melhorar classificação de escala de sonolência epworth, tratar narcolepsia tipo 2, diminuir ou tratar sonolência diurna excessiva, e, composição farmacêutica |
| CN114159568B (zh) * | 2020-09-11 | 2025-08-01 | 北京原基华毅生物科技有限公司 | Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用 |
| MX2023013514A (es) | 2021-05-21 | 2024-04-02 | Purdue Pharma Lp | Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga. |
| TWI804037B (zh) | 2021-11-02 | 2023-06-01 | 長庚醫療財團法人高雄長庚紀念醫院 | 生酮飲食之評估系統及其運作方法 |
| KR20250026332A (ko) * | 2022-06-24 | 2025-02-25 | 퍼듀 퍼머 엘피 | 과민성 방광 증후군의 치료 또는 예방 방법 |
| WO2025085818A1 (en) | 2023-10-19 | 2025-04-24 | Purdue Pharma L.P. | Sunobinop for use in method of treating alcohol use disorder |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| ES2247604T3 (es) | 1995-06-12 | 2006-03-01 | G.D. SEARLE & CO. | Composiciones que comprenden un inhibidor de ciclooxigenasa-2 y un inhibidor de 5-lipoxigenasa. |
| US6572891B1 (en) | 1999-10-23 | 2003-06-03 | Alkaloid Ad | Sublingual oral dosage form |
| JP4056977B2 (ja) | 2002-03-29 | 2008-03-05 | 田辺三菱製薬株式会社 | 睡眠障害治療薬 |
| JP4739217B2 (ja) | 2003-05-07 | 2011-08-03 | サムヤン コーポレイション | 速く溶ける錠剤を製造するための高可塑性顆粒 |
| AR045939A1 (es) | 2003-09-25 | 2005-11-16 | Solvay Pharm Bv | Derivados de bencimidazolona y quinazolinona como agonistas de los receptores orl 1 humanos |
| US7355045B2 (en) | 2004-01-05 | 2008-04-08 | Applera Corporation | Isotopically enriched N-substituted piperazine acetic acids and methods for the preparation thereof |
| WO2006025267A1 (ja) * | 2004-08-31 | 2006-03-09 | Mitsubishi Pharma Corporation | Per2タンパク質レベルの低下を作用機序とする睡眠障害治療薬 |
| WO2008033024A2 (en) | 2006-09-15 | 2008-03-20 | Echo Pharmaceuticals B.V. | Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances |
| MY150602A (en) * | 2007-08-31 | 2014-01-30 | Purdue Pharma Lp | Subtituted-quinoxaline-type piperidine compounds and the uses thereof |
| TWI441658B (zh) | 2008-03-11 | 2014-06-21 | Takeda Pharmaceutical | 口腔崩解固體製劑 |
| KR101333660B1 (ko) * | 2008-07-21 | 2013-11-27 | 시오노기세이야쿠가부시키가이샤 | 치환-퀴녹살린-형 가교-피페리딘 화합물 및 그의 용도 |
| AU2012324015A1 (en) | 2011-12-01 | 2013-06-20 | Purdue Pharma L.P. | Azetidine-substituted quinoxaline-type piperidine compounds and uses thererof |
| WO2014102592A2 (en) | 2012-12-27 | 2014-07-03 | Purdue Pharma L.P. | Oxime/substituted quinoxaline-type piperidine compounds and uses thereof |
| US10118927B2 (en) * | 2012-12-27 | 2018-11-06 | Purdue Pharma L.P. | Substituted piperidin-4-amino-type compounds and uses thereof |
| JOP20190008A1 (ar) | 2016-07-26 | 2019-01-24 | Purdue Pharma Lp | علاج ومنع اضطرابات النوم |
-
2017
- 2017-06-16 JO JOP/2019/0008A patent/JOP20190008A1/ar unknown
- 2017-07-25 KR KR1020197004527A patent/KR102210209B1/ko active Active
- 2017-07-25 WO PCT/IB2017/054506 patent/WO2018020418A1/en not_active Ceased
- 2017-07-25 EP EP17758282.2A patent/EP3490563A1/en active Pending
- 2017-07-25 KR KR1020217002556A patent/KR102531366B1/ko active Active
- 2017-07-25 BR BR112019001457-8A patent/BR112019001457A2/pt not_active Application Discontinuation
- 2017-07-25 CA CA3031388A patent/CA3031388C/en active Active
- 2017-07-25 SG SG11201900486WA patent/SG11201900486WA/en unknown
- 2017-07-25 US US16/318,686 patent/US10974081B2/en active Active
- 2017-07-25 NZ NZ750817A patent/NZ750817A/en unknown
- 2017-07-25 JP JP2019503994A patent/JP7198197B2/ja active Active
- 2017-07-25 TW TW106124940A patent/TWI661827B/zh active
- 2017-07-25 AU AU2017304898A patent/AU2017304898B2/en active Active
- 2017-07-25 MX MX2019001036A patent/MX388469B/es unknown
- 2017-07-25 TN TNP/2019/000019A patent/TN2019000019A1/en unknown
- 2017-07-25 CN CN201780046414.XA patent/CN109689058B/zh active Active
-
2019
- 2019-01-17 IL IL264294A patent/IL264294B/en unknown
- 2019-01-25 CL CL2019000190A patent/CL2019000190A1/es unknown
- 2019-01-25 PH PH12019500177A patent/PH12019500177A1/en unknown
- 2019-02-19 ZA ZA2019/01055A patent/ZA201901055B/en unknown
- 2019-02-26 EC ECSENADI201914247A patent/ECSP19014247A/es unknown
-
2020
- 2020-11-19 AU AU2020273332A patent/AU2020273332B2/en active Active
-
2021
- 2021-03-08 US US17/195,434 patent/US11738023B2/en active Active
- 2021-04-21 JP JP2021072166A patent/JP7291172B2/ja active Active
-
2023
- 2023-06-28 US US18/343,182 patent/US12370191B2/en active Active
-
2025
- 2025-06-16 US US19/239,541 patent/US20260007660A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021120379A5 (https=) | ||
| JP2010535805A5 (https=) | ||
| Gancher et al. | Absorption of apomorphine by various routes in parkinsonism | |
| JP2022537551A5 (https=) | ||
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| RU2007140348A (ru) | Способы и композиции для лечения заболеваний цнс | |
| JP2005515966A5 (https=) | ||
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| JP2006506378A5 (https=) | ||
| JP2010521417A5 (https=) | ||
| RU2006101225A (ru) | Пероральные лекарственные формы мемантина | |
| JP2023552700A5 (https=) | ||
| RU2010109359A (ru) | Азитромицин для лечения кожных заболеваний | |
| JP2016507500A5 (https=) | ||
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| AU2024327500A1 (en) | Topical administration of glp-1 receptor agonists | |
| IL275875B2 (en) | Sleep disorder treatment and prevention | |
| JP2016505050A5 (https=) | ||
| JP2002544227A5 (https=) | ||
| JPH10505087A (ja) | 非麻薬性鎮痛剤および無痛エンハンサーを含有する疼痛緩和組成物 | |
| IL272834B1 (en) | Compositions of amantadine, their preparation, and methods of use | |
| JP2020533402A5 (https=) | ||
| JP2008534523A5 (https=) | ||
| JP2017508737A5 (https=) | ||
| JP2025508052A5 (https=) |